Please sign in to follow a disease.
Meditation brain study in Parkinson's withdrawn before starting
NCT ID NCT05103618
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study planned to use brain scans to measure how a meditation technique called OM affects dopamine and stress markers in people with Parkinson's disease. It was withdrawn before enrolling any participants, so no results are available. The goal was to better understand meditation's potential impact on brain health in Parkinson's.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- OM Meditation (behavioral) and [F-18] Fluorodopa (imaging tracer)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Started
-
Jul 2021
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
25 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria:(Control Group: 6 healthy, normal couple pairs) 1. No clinical diagnosis of PD 2. Age 25 years old and older 3. Physically independent, ambulatory 4. Women of childbearing potential will confirm a negative pregnancy test and must practice effective contraception during the period of pilot study. In addition, male subjects who have a partner of childbearing age should practice effective contraception. Inclusion Criteria for Female Partner in Couple Pairs in Parkinson's Group who has Parkinson's Disease 1. Clinical diagnosis of PD in female partner 2. Age 30 years old and older 3. Physically independent, ambulatory 4. Hoehn and Yahr score of I-III inclusive. 5. On stable antiparkinsonian medication for at least one month 6. Women of childbearing potential will confirm a negative pregnancy test and must practice effective contraception during the period of pilot study. In addition, male subjects who have a partner of childbearing age should practice effective contraception. Inclusion Criteria for Second Partner with No PD in Couple Pairs in Parkinson's Group 1. No clinical diagnosis of PD 2. Age 25 years old and older 3. Physically independent, ambulatory 4. Women of childbearing potential will confirm a negative pregnancy test and must practice effective contraception during the period of pilot study. In addition, male subjects who have a partner of childbearing age should practice effective contraception. Exclusion Criteria: (In Control Couple Pairs and in Couple Pairs Group in which the Female member has PD) 1. Previous brain surgery. 2. Cognitive impairment by evaluation or known score on Mini-Mental Status examination of 25 or lower. 3. Wheelchair-bound or bed-ridden, non-ambulatory. 4. Intracranial abnormalities that may complicate interpretation of the brain scans (e.g., stroke, tumor, vascular abnormality affecting the target area). 5. Diagnosis of traumatic brain injury with significant impairment. 6. Any medical disorder or physical condition that could reasonably be expected to interfere with the assessment of parkinsonian syndrome symptoms, or with any of the study assessments including the PET-MRI imaging. 7. No metal in their body that would prevent MRI scanning (as determined by the PI). 8. Subjects with evidence of a significant psychiatric disorder by history/examination that would prevent completion of the study will not be allowed to participate. 9. Subjects with current alcohol or drug abuse. 10. Pregnant or lactating women. 11. Enrollment in active clinical trial/ experimental therapy within the prior 30 days. 12. Pending surgery during the course of the study. 13. History of thrombocytopenia or clotting disorders. 14. Cancer patients receiving active chemotherapy. 15. History of uncontrolled diabetes and/or thyroid conditions. 16. History of severe kidney disease (if a subject reports this problem, a serum creatinine will be checked to assess glomerular filtration rate (GFR) and if it is less than 30, they will be excluded).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Idiopathic Parkinson disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Thomas Jefferson University, Marcus Institute of Integrative Health Centers
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Reading the Brain's signals to predict who benefits from deep brain stimulation
- Giving Parkinson's patients a say may boost their Brain's ability to learn movement
- Brain scans probe why some Parkinson's patients freeze Mid-Step
- Can tango rewire the brain? dance program tested for Parkinson's and dementia
- Can a workout after walking practice help Parkinson's patients learn better?